Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use

Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In recent decades, several clinical trials have focused on reducing periprocedural ischemic events in patients undergoing P...

Descripción completa

Detalles Bibliográficos
Autores principales: Capodanno, Davide, Milluzzo, Rocco P., Angiolillo, Dominick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906352/
https://www.ncbi.nlm.nih.gov/pubmed/31823688
http://dx.doi.org/10.1177/1753944719893274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906352/
https://www.ncbi.nlm.nih.gov/pubmed/31823688
http://dx.doi.org/10.1177/1753944719893274

Ejemplares similares